Success Metrics

Clinical Success Rate
33.3%

Based on 3 completed trials

Completion Rate
33%(3/9)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
6(60%)

Phase Distribution

Ph phase_2
2
20%
Ph phase_1
8
80%

Phase Distribution

8

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
8(80.0%)
Phase 2Efficacy & side effects
2(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

30.0%

3 of 10 finished

Non-Completion Rate

70.0%

7 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(3)
Terminated(7)

Detailed Status

Terminated6
Completed3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (80.0%)
Phase 22 (20.0%)

Trials by Status

withdrawn110%
completed330%
terminated660%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

NCT00427856
terminatedphase_1

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

NCT00724841
completedphase_1

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT00407303
terminatedphase_1

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

NCT00538187
completedphase_1

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

NCT00521144
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00427856Phase 2

Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

Completed
NCT00724841Phase 1

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

Terminated
NCT00407303Phase 1

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Completed
NCT00538187Phase 1

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

Terminated
NCT00521144Phase 1

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

Completed
NCT00719901Phase 1

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated
NCT00933985Phase 1

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Terminated
NCT00612612Phase 1

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Terminated
NCT01238146Phase 1

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Withdrawn
NCT00918931Phase 2

Obatoclax for Systemic Mastocytosis

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10